Abstract
Signet-ring cell adenocarcinoma is a rare subtype of the uterine cervix; thus there are no guidelines and the prognosis is unknown. There seems to be a significant role for reporting the treatment and outcome of this rare disease in order to establish guidelines and to assist in decision-making. However, treatment should be tailored to each patient according to clinical status and disease stage. Excluding extra-genital origin is mandatory, as it will change treatment management considerably.
Original language | English |
---|---|
Pages (from-to) | 353-354 |
Number of pages | 2 |
Journal | European Journal of Gynaecological Oncology |
Volume | 34 |
Issue number | 4 |
State | Published - 2013 |
Externally published | Yes |
Keywords
- Adenocarcinoma
- Cervical cancer
- Radiotherapy
- Signet-ring cell